Stay updated on Pembrolizumab in Recurrent Respiratory Papilloma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent Respiratory Papilloma Clinical Trial page.

Latest updates to the Pembrolizumab in Recurrent Respiratory Papilloma Clinical Trial page
- Check5 days agoChange Detected- Added a site-wide notice about a lapse in government funding and NIH Clinical Center status with references to cc.nih.gov and opm.gov. Updated the page revision to v3.4.1, replacing the previous v3.4.0.SummaryDifference0.5%

- Check12 days agoChange DetectedFooter and header metadata were updated to include new labels such as 'Last Update Submitted that Met QC Criteria' and 'Last Update Posted', the glossary toggle option, and a revision note 'Revision: v3.4.0'. No changes were made to the study content or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check19 days agoNo Change Detected
- Check48 days agoChange DetectedA unified Locations section appears with Illinois and Massachusetts, replacing prior separate location headings. The revision is updated to v3.3.3.SummaryDifference0.4%

- Check76 days agoChange DetectedRevision note updated from v3.2.0 to v3.3.2. There are no user-facing changes to the study details.SummaryDifference0.1%

- Check83 days agoChange DetectedThe government funding lapse notice and operating-status information (including links to cc.nih.gov and opm.gov) has been removed from the page. This notice previously informed users about potential delays and where to check status updates.SummaryDifference0.4%

- Check98 days agoChange DetectedNo significant additions or deletions were detected; core study information (title, purpose, eligibility, endpoints) and the page’s primary functions remain unchanged.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab in Recurrent Respiratory Papilloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent Respiratory Papilloma Clinical Trial page.